FDA approves BeiGene’s IND for BGB-3111 to treat B-cell malignancies
BGB-3111 is the company’s investigational, oral, highly selective and potent inhibitor of BTK, a critical component of B-cell receptor (BCR) signaling that plays a major role in B-cell
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.